Lanoxin

Digoxin, the active ingredient in Lanoxin, is a cardiac glycoside presented as an injectable solution for intravenous use. It is employed to improve cardiac contractility and control ventricular rate in patients with heart failure and atrial fibrillation.

GNH USA supplies Lanoxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across EU and global markets. The product complies with EU pharmacopeial standards and is packaged in sterile vials suitable for hospital pharmacy preparation.

Digoxin is a cardiac glycoside used in conditions where enhanced cardiac contractility or rate control is required.

- Heart failure: improves ventricular contractility and reduces symptoms of fluid overload. - Atrial fibrillation: slows atrioventricular nodal conduction to control ventricular rate. - Selected supraventricular arrhythmias: provides rate control when other agents are unsuitable.

Adverse reactions to digoxin may range from mild to life‑threatening.

Common Side Effects: - Nausea - Vomiting - Dizziness - Blurred vision - Fatigue - Headache

Serious or Rare Side Effects: - Cardiac arrhythmias (e.g., premature ventricular contractions) - Severe bradycardia or heart block - Hyperkalemia - Allergic skin reactions - Visual disturbances such as yellow‑green halos

When using digoxin, careful monitoring and patient assessment are essential.

- Monitor serum digoxin levels: maintain within therapeutic range to avoid toxicity. - Assess renal function: impaired clearance may require dose adjustment. - Check electrolytes (especially potassium and magnesium): correct abnormalities before initiating therapy. - Use caution in elderly patients: increased sensitivity to drug effects. - Contraindicated in patients with ventricular fibrillation or advanced AV block. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Digoxin interacts with several medicines that can alter its plasma concentration or cardiac effects.

Major Interactions (Avoid): - Amiodarone: markedly increases digoxin levels, raising toxicity risk. - Verapamil or diltiazem: potentiate digoxin effects and may cause bradyarrhythmias. - Quinidine: raises digoxin concentrations and can precipitate toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): may cause electrolyte disturbances that predispose to digoxin toxicity. - Beta‑blockers: additive slowing of AV nodal conduction, requiring careful rate monitoring.